Ionis Pharmaceuticals (NASDAQ:IONS) issued its earnings results on Tuesday. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.13, MarketWatch Earnings reports. Ionis Pharmaceuticals had a negative net margin of 7.20% and a negative return on equity of 1.22%. The company had revenue of $145.40 million for the quarter, compared to the consensus estimate of $146.77 million. During the same period in the previous year, the firm earned ($0.02) earnings per share. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis.
Shares of NASDAQ IONS traded down $0.29 during mid-day trading on Wednesday, hitting $53.65. The stock had a trading volume of 14,423 shares, compared to its average volume of 1,192,375. The company has a quick ratio of 8.34, a current ratio of 8.38 and a debt-to-equity ratio of 0.76. Ionis Pharmaceuticals has a 1 year low of $39.07 and a 1 year high of $57.92. The company has a market cap of $7.10 billion, a price-to-earnings ratio of 667.31 and a beta of 2.39.
In other Ionis Pharmaceuticals news, COO Brett P. Monia sold 16,493 shares of the business’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $54.00, for a total transaction of $890,622.00. Following the transaction, the chief operating officer now directly owns 24,834 shares of the company’s stock, valued at approximately $1,341,036. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP C Frank Bennett sold 12,500 shares of the business’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $49.54, for a total transaction of $619,250.00. Following the transaction, the senior vice president now directly owns 31,896 shares in the company, valued at $1,580,127.84. The disclosure for this sale can be found here. 2.44% of the stock is owned by insiders.
IONS has been the topic of several analyst reports. ValuEngine raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Morgan Stanley decreased their target price on shares of Ionis Pharmaceuticals from $49.00 to $45.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 28th. Piper Jaffray Companies set a $50.00 target price on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a research note on Monday, September 24th. Stifel Nicolaus lifted their target price on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a “hold” rating in a research note on Tuesday, September 25th. Finally, Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $52.00 target price on the stock in a research note on Tuesday, July 10th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $53.86.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.